相关实验视频

Updated: Jan 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

雷戈拉菲尼布是一种多位激酶抑制剂,通过抑制MAPK通路来抑制肠道病毒71感染

Xinyu Zhang¹, Yuanyuan Cao¹, Yu Liu¹

¹Department of Microbiology, Anhui Province Key Laboratory of Zoonoses, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.

International journal of antimicrobial agents

|January 6, 2026

概括

抗癌药物雷戈拉芬尼 (Regorafenib) 显示出强大的抗病毒作用,对抗手足口腔疾病的原因 - - 肠道病毒71 (EV71). 这项研究表明,regorafenib可能是治疗儿童严重的EV71感染的潜在治疗方法.

科学领域:

病毒学病毒学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

肠道病毒71 (EV71) 是手足口病 (HFMD) 的首要原因,对幼儿构成重大风险.
虽然存在EV71 C4疫苗,但严重病例缺乏有效的直接抗病毒治疗方法.

研究的目的:

调查regorafenib的抗病毒潜力,一种已知的激酶抑制剂,对EV71和其他人类肠道病毒.
阐明regorafenib在抑制EV71复制中的作用机制.

主要方法:

在体外抗病毒试验和EV71感染的小鼠模型被用于评估regorafenib的疗效.
机理学研究包括评估regorafenib对MAPK/ERK信号通路的影响.
用分子对接来预测regorafenib与EV71体蛋白VP1.1.之间的相互作用.

主要成果:

雷戈拉费尼布对EV71具有强大的抗病毒活性,对多种人类肠道病毒具有广泛的疗效.
在小鼠模型中,口服雷戈拉费尼布显著降低了EV71症状和病毒载量.
雷戈拉菲尼布通过抑制MAPK通路内的MEK/ERK酸化来抑制EV71.

结论:

雷戈拉费尼布对EV71具有显著的抑制活性,表明其作为一种新型抗病毒剂的潜力.
这些发现支持对regorafenib进一步进行临床前开发,用于治疗EV71感染.
雷戈拉费尼布的机制涉及干扰病毒诱导的MAPK信号传递,并可能与病毒囊结合.

关键词:

这是一种卡普西德抑制剂.在EV71中使用EV71 这是一个HFMD.通过MAPK路径.雷戈拉费尼布的使用情况

更多相关视频

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...